Search Results for "hansten"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for hansten. Results 211 to 220 of 433 total matches.
Pediarix - a Combined Vaccine for Infants
The Medical Letter on Drugs and Therapeutics • May 12, 2003 (Issue 1156)
. Hansten, Pharm. D., University of Washington; Neal H. Steigbigel, M.D., New York University School ...
A new pentavalent vaccine (Pediarix - GlaxoSmithKline), licensed by the FDA for children 6 weeks to 7 years old, includes the antigens from vaccines already marketed against diphtheria, tetanus and pertussis (Infanrix) and hepatitis B (Engerix-B), and a new inactivated polio component.
Minimal Surgery for Treatment of GERD
The Medical Letter on Drugs and Therapeutics • Sep 01, 2003 (Issue 1164)
., Rockefeller University
CONTRIBUTING EDITORS: Philip D. Hansten, Pharm. D., University of Washington; Neal H ...
Laparoscopic surgery has become increasingly popular for the treatment of gastroesophageal reflux disease (GERD). The usual surgical procedure, a Nissen fundoplication, prevents reflux into the esophagus. The review compares medical treatment with a proton pump inhibitor vs. surgical therapy as well as open vs. the new laparoscopic technique. Morbidity and mortality with the procedures are discussed.
Vardenafil (Levitra) for Erectile Dysfunction
The Medical Letter on Drugs and Therapeutics • Sep 29, 2003 (Issue 1166)
: Martin A. Rizack, M.D., Ph.D., Rockefeller University CONTRIBUTING EDITOR: Philip D. Hansten, Pharm. D ...
Vardenafil (Levitra -Bayer) is the second oral drug approved by the FDA for treatment of erectile dysfunction. Sildenafil (Viagra - Medical Letter 1998; 40:51), the first oral drug, has been available for 5 years. Pharmacokinetics, effectiveness, adverse effects, dosage and cost of the new drug are reviewed. Whether it offers any benefits over sildenafil is discussed.
Tattoo Removal
The Medical Letter on Drugs and Therapeutics • Nov 24, 2003 (Issue 1170)
., Rockefeller University CONTRIBUTING EDITOR: Philip D. Hansten, Pharm.D., University of Washington
ADVISORY ...
While more people than ever are getting tattoos, many come to regret their decision and would like to have them removed. The technology of removing tattoos is much better than it used to be, but still far from perfect. Complete removal of all pigments with restoration of normal skin color and texture is not always possible (M Kuperman-Beade et al, Am J Clin Dermatol 2001; 2:21; GM Lipper and RR Anderson in IM Freedberg et al, eds, Fitzpatrick's Dermatology in General Medicine 6th ed, New York:McGraw-Hill 2003, page 2508).
Efalizumab (Raptiva) for Treatment of Psoriasis
The Medical Letter on Drugs and Therapeutics • Dec 08, 2003 (Issue 1171)
, M.D., Ph.D., Rockefeller University CONTRIBUTING EDITOR: Philip D. Hansten, Pharm.D., University ...
Efalizumab (Raptiva - Genentech/XOMA), a humanized monoclonal antibody that inhibits T-cell activation, has been approved by the FDA for treatment of adults with moderate to severe chronic plaque psoriasis.
Alfuzosin (Uroxatral) -- Another Alpha1-blocker for Benign Prostatic Hyperplasia
The Medical Letter on Drugs and Therapeutics • Jan 05, 2004 (Issue 1173)
, M.D., Ph.D., Rockefeller University CONTRIBUTING EDITOR: Philip D. Hansten, Pharm.D., University ...
Alfuzosin hydrochloride (Uroxatral - Sanofi-Synthelabo) is now available in the US in a new formulation for once-daily treatment of benign prostatic hyperplasia (BPH). The drug has been used in Europe since 1987. Alpha1-blockers cause relaxation of smooth muscle tone in the bladder neck, prostatic capsule and prostatic urethra, relieving symptoms of urinary obstruction.
Stalevo for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • May 10, 2004 (Issue 1182)
EDITOR: Martin A. Rizack, M.D., Ph.D., Rockefeller University ADVISORY BOARD: Philip D. Hansten, Pharm.D ...
Levodopa combined with carbidopa (Sinemet, and others) is the most widely used treatment for patients with Parkinson's disease, but after 2 to 5 years most patients develop troublesome complications (Treatment Guidelines from The Medical Letter 2004; 2:41). The newest treatment for Parkinson's disease patients with end-of-dose "wearing-off" is Stalevo (Novartis), a combination of the catechol-O-methyltransferase (COMT) inhibitor entacapone (Comtan) with 3 different doses of levodopa/carbidopa. The rationale for Stalevo is that it permits some patients to take only one pill rather than...
Catheter Ablation for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jul 19, 2004 (Issue 1187)
., Ph.D., Rockefeller University ADVISORY BOARD: Philip D. Hansten, Pharm.D., University of Washington ...
Advertisements are appearing in medical journals for continuing medical education courses on catheter ablation of atrial fibrillation. Is a cure at hand for this common disorder?
Do NSAIDs Interfere with the Cardioprotective Effects of Aspirin?
The Medical Letter on Drugs and Therapeutics • Aug 02, 2004 (Issue 1188)
BOARD: Philip D. Hansten, Pharm.D., University of Washington; Jules Hirsch, M.D.,
Rockefeller ...
Low-dose aspirin is widely used as an antiplatelet drug to reduce the risk of cardiovascular disease (Medical Letter 2000; 42:18). Recent reports suggest that the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen (Motrin, and others) may decrease the efficacy of aspirin for this indication. The manufacturer of Tylenol is capitalizing on these reports by advertising that aspirin-taking patients who need pain relief should use acetaminophen instead of ibuprofen.
Menostar - A Low-Dose Estrogen Patch for Osteoporosis
The Medical Letter on Drugs and Therapeutics • Aug 30, 2004 (Issue 1190)
ADVISORY BOARD: Philip D. Hansten, Pharm.D., University of Washington; Jules Hirsch, M.D.,
Rockefeller ...
The FDA has approved a new low-dose estrogen patch (Menostar - Berlex) for prevention of osteoporosis in postmenopausal women. Unlike other estrogen patches, it is not approved for treatment of hot flashes or other menopausal symptoms. Promotional material from the manufacturer suggests that this low dose of estrogen could prevent osteoporosis without some of the adverse effects of higher doses.